Acute Hepatitis Associated with “Thermogenic Fat Burner” Weight-Loss Supplementation

Marko Popovic MD(C), Maxime Billick MD, CM, Matthew R. Robinson MD, CM, FRCPC

Abstract
Thermogenic fat burner treatments are used to increase an individual's basal metabolic rate, thus mimicking exercise and inducing weight loss. In rare circumstances, these supplements are associated with hepatotoxicity. We describe the case of a 21-year-old male who presented with painless jaundice and a weight loss of 25% of body weight following 8 weeks of thermogenic fat burner supplementation. Laboratory investigations revealed a severe transaminase and bilirubin elevation (AST/ALT>2000 IU/L, total bilirubin=148 μmol/L). An otherwise extensive workup, including a liver biopsy, did not identify a precise cause. Two weeks after discharge, his condition stabilized with a significant improvement in his laboratory abnormalities. In this report, we discuss the likely ingredients that contributed to the patient's condition, including Garcinia cambogia and green tea leaf extract, and review similar cases documented in the literature.

Case Report
In September 2017, a 21-year-old male presented to his local emergency department in Toronto, Canada with a one-day history of painless jaundice, dark urine, dizziness, and nausea. In May 2017, the patient began increasing his exercise frequency to 5 days per week and improving his diet to lose weight. Additionally, he consumed the following oral supplements for an 8-week course of appetite suppression: Evlution Nutrition Lean Mode Stimulant-Free Weight Loss Supplement™ (3 capsules every 12 hours) (Table 1A) and Evlution Nutrition Trans4orm Thermogenic Fat Burner™ (2 capsules every 12 hours) (Table 1B).

In 8 weeks, he lost approximately ¼ of his body weight (initial weight: 200 lbs, final weight: 150 lbs). At presentation, he had stopped supplementation use for 4 weeks as he achieved his weight-loss goals. His social history was also significant for alcohol use of approximately 10–20 drinks per week during this time, predominantly occurring at social gatherings. Two weeks after supplement discontinuation, he began producing consistent dark urine despite 3–4 litres of water intake daily, which was followed by episodes of nausea, vomiting, and headache several days later. Throughout this period, his functional status was unchanged and he did not experience any concurrent illness.

On examination, his vital signs were stable, and his abdomen was non-tender and without organomegaly. Examination was otherwise notable for jaundice with scleral icterus. He was
Table 1B. Ingredient List – Evlution Nutrition Trans4orm Thermogenic Fat Burner™

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount (ingredients per 2 capsules)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green tea leaf extract</td>
<td>500 mg</td>
</tr>
<tr>
<td>Bitter orange peel powder</td>
<td>400 mg</td>
</tr>
<tr>
<td>L-tyrosine</td>
<td>175 mg</td>
</tr>
<tr>
<td>Choline bitarate</td>
<td>150 mg</td>
</tr>
<tr>
<td>Alpha-glycerolphosphorylcholine powder</td>
<td>25 mg</td>
</tr>
<tr>
<td>BioPerine (black pepper fruit extract)</td>
<td>5 mg</td>
</tr>
<tr>
<td>Niacin</td>
<td>15 mg</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>2 mg</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>6 μg</td>
</tr>
<tr>
<td>Chromium picolinate</td>
<td>120 μg</td>
</tr>
<tr>
<td>Other ingredients: gelatin, natural caffeine (from coffee bean), silicon dioxide, folic acid</td>
<td></td>
</tr>
</tbody>
</table>
immune-mediated with an elevation in anti-nuclear antibody and anti-smooth muscle antibody. At the time, this represented the first described case of an immune-mediated hepatitis from Hydroxycut, which is typically associated with a hepatocellular pattern of liver injury. Her symptoms and condition eventually resolved without sequelae.

In 2010, Sharma et al. reported the first case of Hydroxycut hepatotoxicity in Hawai’i. They described the case of a 19-year-old male presenting with a 2-day history of fever, myalgias, scleral icterus, and an erythematous rash over the lower extremities presumed secondary to acute cholangitis with hyperbilirubinemia. One week previously he began using Hydroxycut. He was admitted and received broad-spectrum antibiotics; however, no infectious etiology could be determined. He was discharged after 17 days in hospital, with a gradual recovery of laboratory abnormalities and normalization by 14 weeks after onset. In their literature review, the authors note that even though certain Hydroxycut preparations have been withdrawn from the market by the manufacturer, similar products exist that may lead to adverse events.

Following the recall of Hydroxycut by its manufacturer, Fong et al. in 2010 described a case series which sought to characterize the clinical presentation of drug-induced liver injury. Typical symptoms included jaundice, fatigue, nausea, vomiting, and abdominal pain. Most cases of hepatitis were associated with a hepatocellular pattern. All patients were admitted to hospital, and 3 of 8 required liver transplantation. One patient on the FDA MedWatch database died secondary to acute liver failure. When all 17 cases were considered, 8 were definitely related to Hydroxycut ingestion, while 5 were highly likely, 2 were probable, and 2 were possibly related.

In contrast, Chuah et al. performed a review of clinical toxicities of Hydroxycut in 2012. They reviewed multiple cases in which HCA was suspected to cause hepatotoxicity and determined that adverse reactions were associated with polyherbal or multicomponent products. In addition, many of the products contained HCA in negligible amounts or occasionally not at all. They stressed that it was not possible to establish causality based on association, as it was not known which ingredients in the products were responsible for the adverse liver effects. Based on the findings of 17 clinical studies and 873 subjects, they concluded that the level for no observed adverse effects in HCA is up to 2800 mg/day. This is a higher threshold than what was reported to be consumed by our patient.

It is important to acknowledge that our patient had a total exposure of 8 weeks to supplementation, during which time he did not develop symptoms. It is possible that he may have had subclinical laboratory abnormalities during this time. Nonetheless, our literature review of previous cases shows that it is uncommon for symptoms to appear 2 weeks after supplementation discontinuation, as was the case in our patient.

While HCA was strongly suspected to be associated with hepatotoxicity in our patient, the impact of other ingredients should not be discounted. Green tea leaves are the only other ingredient labelled in his supplements that have been associated with hepatotoxicity. Green tea leaves are taken as supplements for their presumed health benefits, including promotion of weight loss, due to intrinsic antioxidant activity. The leaves are composed of catechins, including epigallocatechin–3–gallate, which have been implicated as causes of liver damage via mitochondrial toxicity and reactive oxygen species generation within hepatocytes. A systematic review noted the potential of green tea extract to cause hepatotoxicity. In short, green tea extract may have contributed to hepatocyte injury and thus hepatitis; however, there is stronger evidence supporting the association of acute hepatitis with Garcinia cambogia, as illustrated above.

Beyond hepatotoxic supplementation, alcohol likely contributed to our patient’s condition. A landmark article by Cohen and Kaplan showed that in 98% of patients with alcoholic liver disease, the increase in ALT was less than 6–7 times the upper end of normal (i.e., ALT increase of 240–280). As a result, the observed increase in transaminases was likely not attributable to alcohol alone; however, it may have been a contributory factor. Prior reports discussed above do not specifically comment on the use of alcohol as a potential contributory factor to the hepatotoxicity that was observed.

In summary, we present the case of a 21-year-old male with acute hepatitis likely due to weight-loss supplementation containing HCA and green tea leaf extract. Significant alcohol use was likely a contributing factor, but was unlikely to account for the majority of his clinical presentation. Healthcare professionals are encouraged to be aware of these associations and to always conduct a thorough history of complementary and alternative medicines when evaluating patients with acute hepatitis.

**Financial Support**
None.

**Acknowledgements**
None.

**Conflicts of Interest**
None.

**Consent**
The authors have obtained patient consent for participation in this study.
Contributors
All of the authors wrote and revised the article, gave final approval of the version to be published and agreed to act as guarantors of the work.

References